Triera Biosciences is a wholly owned subsidiary of Zentek Ltd.
Through advancements in next-generation materials like graphene and other innovative developments, Zentek is discovering new ways to protect against pathogens, detect and treat disease, make building materials stronger, and produce cleaner energy.
Triera Biosciences is pioneering a transformative aptamer platform with potential for development of new treatments. Preclinical trials have demonstrated efficacy that have matched or exceeded monoclonal antibodies.